Biovail Faces Grand Jury Probe On Cardizem Launch

Law360, New York (February 1, 2008, 12:00 AM EST) -- The U.S. attorney's office in Boston is now pursuing a grand jury investigation into Biovail Corp.'s launch of the hypertension drug Cardizem(R) LA, a move that has already come under scrutiny in a securities class action.

Biovail announced on Friday that the U.S. attorney had informed the company that it was the subject of a grand jury inquiry into its activities surrounding the 2003 introduction of Cardizem(R) LA.

“As previously disclosed, the investigation commenced in 2003 as an administrative inquiry,” Biovail said. “The corporation has been...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.